US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Brighter's main patent has been approved by United States Patent and Trademark Office.

The United States Patent and Trademark Office (USPTO) has granted Brighter's main patent in the United States, which includes Actiste and its unique ability to integrate all functions in a patient's activity chain into one and the same device, i.e. measuring and analyzing a biomarker (e.g. blood glucose), and injecting medicine (e.g. insulin). “The approval of our main patent means that an important piece in our global expansion plan is now in place. The potential in the United States is enormous given the large number of people living with diabetes there and across the entire American

Brighter participates in Telia’s Digital Healthcare event in Almedalen.

Truls Sjöstedt, Brighter's CEO, is invited as speaker on Telia's event "Connected people do not need to be patients" in Almedalen, on July 4th 11:00-12:00 CEST. The event is held at Wisby Strand Congress & Event, Donnersgatan 2, Visby. Complications from chronic diseases lead to impaired quality of life and a great deal of suffering for the patients. The yearly cost for society is huge. Swedish National Board of Health and Welfare estimates that in diabetes care, which costs Sweden around SEK 9 billion yearly, complications represents 92 percent of the total cost. With modern technology,

Brighter invited as speaker for diabetes event with Cambridge Wireless and Cambridge University Health Partners.

Henrik Norström, Brighter’s COO, is invited as speaker to discuss Actiste’s and The Benefit Loop’s role in revolutionizing today's diabetes care at the event ‘Unlocking ‘Remote Monitoring’ for Effective Diabetes Care’, organized by Cambridge Wireless and Cambridge University Health Partners. The event focuses on how sensors, data analysis and connected mobile solutions can streamline diabetes care and how new technologies is enabling a more proactive care for better long-term results. Learn more about the event and its other participating speakers here 

Brighter represents data-driven health on state visits to Indonesia.

Brighter united with Swedish world-class companies such as Atlas Copco, Getinge, Elekta, IKEA, H&M, Ericsson, Scania, SKF and Volvo in a major venture in Indonesia. Brighter, which develops solutions for data-driven health, participates in Sweden's state visit to Indonesia from 22 to 24 May 2017. The company, which develops Actiste® - a service for insulin-treated diabetics and all relevant stakeholders in their care chain - already has extensive interests in Indonesia. The country today has the world's fourth largest population with its 255 million inhabitants. As early as 2030,

Brighter selects AIS & Ericsson to launch the diabetes solution Actiste in Thailand.

Thailand’s leading mobile phone operator AIS and Ericsson, will be Brighter’s partners for the launch of Actiste in Thailand. The solution will be launched on AIS’s IoT managed connectivity solution and Ericsson’s DCP (Device Connection Platform). In line with Brighter’s launch strategy, mobile operator AIS will be the company’s launch partner in Thailand. Diabetes is growing fast in the region and in 2015 about 4 million people lived with the disease in Thailand. Actiste is a mobile health solution that simplifies insulin-treated diabetes by gathering and sharing important data between

Brighter secures external financing of up to SEK 100 million to support the launch of Actiste® and issues free warrants to its shareholders.

Brighter has signed an agreement relating to an investment of up to SEK 100 million. The capital will be used for the production and the launch of Actiste , the company's unique diabetes service. The transaction is carried out through a private placement of convertible notes with warrants attached in up to eight tranches spread over 36 months. The first Tranche issued by Brighter amounts to SEK 30 million. - This investment will enable us to launch and produce Actiste in order to meet the demand. We are pleased to be able to welcome a large international

Brighter partners with Indonesia Mampu to fight diabetes in Indonesia.

Brighter has signed an agreement for contributing to the development of the first healthcare initiative within Indonesia Mampu, a program of works led by Palladium and the Indonesian government body National Team Secretariat for Accelerating Poverty Reduction (TNP2K). Indonesia Mampu’s partnership framework is aimed at alleviating poverty in Indonesia through a positive impact program based on four pillars of which one is healthcare. As part of this pillar there will be a focus on diabetes prevention and treatment where Brighter’s knowledge and technology will be an important component.

Brighter signs agreement with Sonat for global logistics solution.

Brighter has selected Sonat as its development partner for the upcoming launch of Actiste®, Brighter’s connected diabetes solution. Sonat specializes in developing, managing and running logistics processes, and will together with Brighter develop a strong logistics platform that facilitates growth and international expansion. Under the agreement, Sonat will take on a partner role and drive the development of a logistics platform that enables rapid growth and expansion to new markets. Sonat will also act as an outsourced logistics function, which includes responsibility for forecasts,

Brighter signs agreement to launch the diabetes solution Actiste in Indonesia.

Brighter has chosen Indosat Ooredoo in cooperation with Ericsson as partners for the launch of Actiste in Indonesia. The solution will be launched based on the Ericsson’s DCP (Device Connection Platform) for Connectivity Management. Diabetes is growing fast in the region and in 2015 about 10 million people live with the disease in Indonesia and another 5 million are undiagnosed, according to the International Diabetes Foundation. Actiste will be marketed and sold as a subscription service to both consumers and the healthcare sector. One key driver for Brighter’s focus on Indonesia is

Brighter teams up with Sanmina to manufacture Actiste.

Brighter today announced a partnership with Sanmina to produce the first generation of Actiste®, a connected diabetes device that allows users to monitor blood sugar, inject insulin and log blood sugar levels and insulin doses in a single device.  Sanmina is a global Tier 1 provider of integrated manufacturing solutions, making some of the world’s most complex and innovative electronic and mechanical products. Essential criteria in Brighter’s selection included Sanmina’s substantial experience producing advanced medical devices including millions of diabetes care tools. Sanmina’s

Brighter and Telia sign agreement for subscription services for the Actiste diabetes solution.

The deal means that Brighter’s connected diabetes management solution for insulin-treated diabetes patients, Actiste®, will be available on the Swedish market through Telia’s digital healthcare solution. The deal with Telia, like the partnership initiated with Ericsson in 2015, is an important milestone towards Brighter’s vision for the future of healthcare, and it allows Brighter to move towards the design of a joint launch plan for Actiste.  “Of course we are very happy to finally have a first mobile operator agreement in place. It is clear that Telia shares our vision and idea about

Brighter AB (publ) held its AGM on 2016-05-17.

The annual general meeting voted unanimously in accordance with all proposals from the official notification of the annual general meeting. About Brighter AB (publ)Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and innovative tools, jDome® and Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care and

Brighter’s Private Placement of shares registered.

The Private Placement that Brighter AB (publ) issued and that was completed on April 29 has been registered with the Swedish Companies Registration Office. The shares will be delivered to the shareholders today. Number of new shares issued: 4,556,418 Total number of shares after the issue: 45,937,263 Share capital after the issue: SEK 2,293,863,15 About Brighter AB (publ) Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and innovative tools, jDome® and Actiste™, the company creates a more efficient care chain with

Brighter recruits expert to support the development and launch of Actiste.

In connection to the upcoming launch of Actiste®, Brighter’s new advisor Jorge C. Otero is an important link to the global pharmaceutical industry. Together with the company's management Jorge C. Otero will develop the go to market strategies for Actiste and evaluate additional business areas in which the product can be applied, in addition to diabetes. Jorge C. Otero, MD, has an extensive and documented background in the pharmaceutical industry and has been a senior executive for clinical development and medical affairs at large pharmaceutical companies such as Eli Lilly,

Brighter is negotiating agreements with 5 mobile operators.

Northern Europe and South-East Asia could become the first markets for subscription services agreements for Brighter’s® integrated, online devices for insulin-treated diabetics, Actiste™ Negotiations have commenced and an agreement is expected to be concluded in the first half of 2016.The market for data-driven healthcare is experiencing tremendous growth, as more and more companies are discovering the potential in the market. Brighter – with its cloud-based service The Benefit Loop™ defines how patients and health providers can use patient data to create considerable value for other

Interim Information. January - September 2015.

|       Interim Information January 1 – September 30 2015. · Operating revenues totaled MSEK 1.583 (MSEK 1.233). · Profit/loss after financial items totaled MSEK -6.435 (MSEK -5.802). · Earnings per share before dilution: SEK -0.24. · Earnings per share after dilution: SEK -0.24. |       Financial calendar. Year-end report for 2015: 2016-02-19. Annual Report 2015: 2016-03-24. Interim information January-March 2016: 2016-05-20. Half-Year Report January-June 2016: 2016-08-26. Interim information January-September 2016: 2016-11-25. |       Significant events

Brighter accelerates - rights issue oversubscribed.

Brighter AB (publ) recently implemented a new share issue with preferential rights for existing shareholders who wished to subscribe for units. The issue injected SEK 198 million into the company—corresponding to a 1,219% subscription rate. Nasdaq First North lists the Brighter share under the BRIG ticket.Because the issue was heavily oversubscribed, Brighter’s board decided to make full use of the subscription rights issue worth more than SEK 3 million, which yields total issue proceeds of SEK 19.3 million before issue costs. Through this issue, 16,064,872 new shares were issued. The total

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media

Twitter